In the present study, we used the imatinib-resistant BCR/ABL+ cell line K562/G01 to investigate the role of Nrf2 in conferring imatinib resistance in CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.